Verdinexor: A New Oral Treatment Option for Canine Lymphoma

1 hour CE

In this CE session, we’ll review the latest best practices for managing canine lymphoma. We’ll also talk about how the first FDA conditionally approved oral tablet for canine lymphoma, LAVERDIA™-CA1 (verdinexor), is giving veterinarians and dog owners more options and increasing access to cancer care.

What you'll learn:

  • Evolving protocols for canine lymphoma treatment
  • The role of primary care teams in treating lymphoma
  • How SINE drugs work and why they are different
  • When to consider LAVERDIA-CA1 for lymphoma patients
  • Guidelines to optimize patient outcomes
This program has been approved for 1.0 hour of continuing education credit in jurisdictions that recognize RACE approval. Anivive RACE Provider #50-30163
Anivive Logo

Schedule

Speaker:
Date:
Time:
Jim Lowe Circle Image
Jim Lowe
TuesdayDec 07, 2021
6 PM UTC
Julie Dinnage Circle Image
Julie Dinnage
WednesdayDec 08, 2021
8 PM UTC
Jim Lowe Circle Image
Jim Lowe
ThursdayDec 09, 2021
6 PM UTC
Julie Dinnage Circle Image
Julie Dinnage
TuesdayDec 14, 2021
6 PM UTC
Dan Dreyfuss Circle Image
Dan Dreyfuss
WednesdayDec 15, 2021
6 PM UTC
Julie Dinnage Circle Image
Julie Dinnage
ThursdayDec 16, 2021
6 PM UTC

DON'T SEE A TIME THAT WORKS? WATCH NOW.

Speakers

David Bruyette

Dr. David Bruyette

DVM, DACVIM (SAIM)

Chief Medical Officer

Dan Dreyfuss

Dan Dreyfuss

DVM, MA

Manager, Veterinary Medical Affairs

Julie Dinnage

Julie Dinnage

DVM

Director, Veterinary Medical Affairs

Jim Lowe

Jim Lowe

DVM

Manager, Veterinary Medical Affairs

US Map

Contact your local Anivive speciality sales executive